HNN3.0
Register
Register
Register

Datharsis

Company (SME)

www.datharsis.com/Granada, Spain

About

Datharsis (Explain Tech S.L.) is a deep tech spin-off of the University of Granada, Spain, specialised in the explainable analysis of omics data across the life sciences, from health to agri-food and ecology. We help research teams design their studies and turn high-dimensional, noisy and multimodal data into traceable, reproducible evidence. In research consortia we lead the data analysis work: experimental design, integration of omics, clinical and other complex data, and interpretable, validated results.

Our methods come from twenty years of peer-reviewed research at the Computational Data Science Laboratory (CoDaS Lab) of the University of Granada, and we use them under an exclusive commercial licence from the university. Our Chief Scientific Advisor, Prof. José Camacho, is a Full Professor at the University of Granada, head of CoDaS Lab and ranked in Stanford's top 2% of scientists worldwide. He leads our scientific strategy and our participation in European research projects.

Two things we do:

  • Statistical design of experiments. Many studies fail not in the analysis but in the design. Before any sample is collected, we help define the questions the study must answer, the factors and interactions to include, the sampling strategy and the sample size needed, using our own computational methods. The result is more statistical power with fewer samples, and lower field, laboratory and sequencing costs. In a Horizon Europe proposal, this strengthens the methodology section from the start.

  • Interpretable analysis and integration of omics data. We integrate omics layers (metabolomics, proteomics, transcriptomics, epigenomics, microbiota, spatial omics) with clinical, spectral or environmental data. Our models are interpretable by design, not explained afterwards with post-hoc layers. Methods developed by our team, such as vASCA, group-wise models and MEDA, reveal which variables drive each effect in experiments with several crossed factors. Cross-validation and permutation testing then confirm that the results are robust and not artefacts. See the scientific evidence.

Our team's methods have been applied to:

  • Response to chemotherapy and survival signatures in cancer, using metabolomics

  • Multi-omics profiling of a paediatric cohort, combining microbiota, metabolomics and clinical data

  • The spread of a mycotoxin in wheat varieties over the crop cycle

  • Food authentication and traceability

  • The effect of mistletoe parasitism on the pine metabolome, separated from season, tree and canopy height

  • The effect of contaminants across three tissues of crabs in ecotoxicology studies

  • Warming trends in high mountain lakes, separating the shared climate signal from the features of each lake

These are only some examples. The same methods work wherever data combine several factors, many variables and few samples, and our team has also applied them to volcanic eruption forecasting, industrial process monitoring and network security. See all documented cases.

What we bring to a consortium:

  • Leadership of the data analysis work package, or of specific analysis tasks

  • Study design and sample size planning, from the proposal stage

  • Discovery of interpretable biomarkers, indicators and signatures, with rigorous statistical validation

  • Reproducible, auditable analysis pipelines aligned with FAIR principles

  • DathaSuite, our analysis platform, so consortium researchers can explore their own data with the same methods

  • Training of consortium researchers through our DathaXplain programme

If your project will generate complex omics data and needs results that hold up before reviewers and regulators, let's talk.

Social media

Representatives

CEO & CTO

Datharsis

Marketplace (5)

  • Project cooperation

    Explainable predictive and prognostic biomarkers: interpretable-by-design models for chronic diseases

    Partner for explainable predictive and prognostic biomarkers: interpretable-by-design models on omics, clinical and real-world data, with rigorous validation and study design from the proposal stage.

    • Partner seeks Consortium/Coordinator
    • Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
    Author

    CEO & CTO at Datharsis

    Granada, Spain

  • Project cooperation

    Multi-omics and exposome data integration for environment and health research

    Partner for multi-omics and exposome data integration: combining omics, clinical and environmental exposure data into interpretable models that show which exposures drive which health effects.

    • Partner seeks Consortium/Coordinator
    • Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
    Author

    CEO & CTO at Datharsis

    Granada, Spain

  • Project cooperation

    Study design and statistical analysis partner for clinical trials and intervention studies

    Study design and statistical analysis partner for clinical trials and intervention studies: sample size and factor planning, multi-endpoint analysis and reproducible, auditable pipelines.

    • Partner seeks Consortium/Coordinator
    • Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
    • Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
    Author

    CEO & CTO at Datharsis

    Granada, Spain

  • Project cooperation

    Untangling adverse drug reactions in polypharmacy: multifactor analysis partner

    Multifactor analysis partner for adverse drug reactions and polypharmacy: methods that separate the effect of each drug, dose, age and comorbidity, and their interactions, instead of a black-box score.

    • Partner seeks Consortium/Coordinator
    • Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
    Author

    CEO & CTO at Datharsis

    Granada, Spain